Follow the Pundits
Tag: featured-hedge-funds
Renaissance Technologies in 2025: Quant Quake, Post-Simons Growing Pains & The Limits of the Machine
Even the smartest hedge fund on Earth can stumble. Renaissance Technologies’ public funds struggled in 2025 as quant models collided with narrative-driven markets, policy shocks, and momentum chaos. A fascinating reminder that machines learn — sometimes the hard way.
Principles of Prosperity: How Bridgewater’s AI-Driven “Machine” Built a Fortress in 2025
After years of skepticism, Bridgewater roared back in 2025. Pure Alpha surged, All Weather delivered, and Ray Dalio’s machine pivoted hard into U.S. equities and AI infrastructure. Fortress rebuilt — with a few cracks worth watching.
Citadel’s 2025 Scorecard: No Fireworks, Just Relentless Discipline
Citadel delivered another disciplined year in 2025 — not flashy, but formidable. Here’s what Ken Griffin’s fortress is really doing, and what it means for investors.
Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring
CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯
Fundamental Research–Driven Fund Voss Capital Buys PAR Technology: Time to Shop?
PAR Technology is shifting from legacy hardware to a unified restaurant SaaS platform. After Voss Capital’s $7.1M buy, massive institutional ownership, and heavy short interest, the setup looks like an inflection-point story—high upside if execution clicks, sharp downside if it doesn’t.
Funds Still Love Meta Platforms — Should Retail Add on Dips?
Funds remain heavily invested in Meta Platforms as AI boosts ads and cash flow — but at today’s price, patience may still pay off.
John Rogers’ Ariel Investments Loves Madison Square Garden Entertainment: Should You?
MSGE owns some of the world’s most iconic entertainment venues. Demand is strong — but leverage and price argue for patience.
Nvidia Is a Top-Five Stock Held by Hedge Funds: Should You Buy — or Even Hold?
Nvidia is the crown jewel of AI and a top hedge-fund holding. The company is stellar — but is the stock still worth buying in 2026?
Hedge Funds Like Royalty Pharma: Should Retail Wear the Crown?
Royalty Pharma isn’t a biotech moonshot — it’s a cash-collecting royalty king. Hedge funds are buying, buybacks are flowing, and dividends keep compounding. 👑💊
Hedge Funds Miller Value and Värde Partners Love Nabors Industries’ Cheap Shares, Deleveraging, and Saudi Aramco JV
Hedge funds are circling Nabors Industries — and not by accident. With aggressive deleveraging, a Saudi Aramco joint venture, and valuation metrics that still scream skepticism, NBR may be one of energy’s most misunderstood value plays.